ASCO 2017 – CLL

Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL

ASCO 2017 – CLL

This phase 2 study evaluates the efficacy and safety of bendamustine and obinutuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL). Read More ›

CD19 CAR T-Cells Combined with Ibrutinib to Induce Complete Remission in CLL

ASCO 2017 – CLL

The pilot trial of anti-CD19 chimeric antigen receptor (CAR) T-cells with ibrutinib assessed complete remission in patients with chronic lymphocytic leukemia (CLL). Read More ›

Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study

ASCO 2017 – CLL

The phase 2 AIM study examined the efficacy and safety of the combination of ibrutinib and venetoclax in relapsed/refractory mantle-cell lymphoma (MCL). Read More ›

A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas

ASCO 2017 – CLL

A phase 1 study explores a combination of a novel Bruton’s tyrosine kinase (BTK) inhibitor, DTRMWXHS-12 (DTRM-12), with everolimus and pomalidomide in patients with chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Read More ›

Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)

ASCO 2017 – CLL

The multicenter, randomized, double-blind, placebo-controlled phase 3 PERSPECTIVE study compares the progression-free survival outcomes of ibrutinib with rituximab versus placebo with rituximab in patients with treatment-naïve (TN) follicular lymphoma (FL). Read More ›

Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL

ASCO 2017 – CLL

This phase 1 trial evaluates the safety and efficacy of the triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with B-cell malignancies. Read More ›

ASCO 2017 – CLL

Page 2 of 2